Ozolan (Anastrozole)

Anastrozole is employed in the management of estrogen‑driven conditions, primarily focusing on breast cancer pathways.

• Early‑stage hormone‑receptor‑positive breast cancer: helps ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ reduce ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  tumor growth.
• Advanced or metastatic hormone‑receptor‑positive breast cancer: slows ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  disease progression.
• Prevention of breast cancer recurrence after surgery: lowers ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  risk of new tumor development.

• Anastrozole selectively inhibits the aromatase enzyme, which converts adrenal and peripheral androgen precursors into estradiol. By reducing systemic estrogen levels, it diminishes estrogen‑driven cellular proliferation in hormone‑sensitive tissues, particularly breast cancer cells, thereby slowing tumor growth and recurrence.

Adverse reactions to anastrozole are generally mild to moderate and reflect its hormonal modulation.

Common Side Effects

• Hot flashes
• Joint or muscle pain
• Fatigue
• Nausea
• Headache
• Weight gain

Serious or Rare Side Effects

• Osteoporosis or decreased bone mineral density
• Severe allergic reaction (anaphylaxis)
• Elevated liver enzymes
• Deep vein thrombosis or pulmonary embolism
• Cardiovascular events such as myocardial infarction

When using Ozolan, certain safety measures and monitoring practices are recommended.

• Baseline bone health assessment: evaluate bone mineral density before initiating therapy.
• Periodic liver function tests: monitor hepatic enzymes during treatment.
• Cardiovascular risk evaluation: assess history of thromboembolic events.
• Concomitant hormone therapy: avoid use with estrogen‑containing products.
• Pregnancy and lactation: contraindicated; ensure effective contraception.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Anastrozole may interact with several medicines that influence hormone metabolism or share elimination pathways.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce anastrozole exposure.
• Estrogen‑containing hormone replacement therapy – antagonises therapeutic effect.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (ketoconazole, itraconazole) – may increase plasma levels.
• Warfarin – potential alteration of anticoagulant effect.
• Selective serotonin reuptake inhibitors (SSRIs) – possible additive effect on bone density loss.